Titre : | Amifampridine : LiverTox: Clinical and Research Information on Drug-Induced Liver Injury |
Type de document : | Article |
Editeur : | Bethesda (MD), 05/2019 |
Langues: | Anglais |
Mots-clés : | amifampridine ; article de type review ; effet indésirable ; maladie neuromusculaire ; posologie ; syndrome myasthénique de Lambert-Eaton |
Résumé : |
2012 [Last Update: May 15, 2019] LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Amifampridine. [Updated 2019 May 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547851/
Drug Class: Myasthenia Agents Introduction Amifampridine is an orally available potassium channel blocker that increases acetylcholine in synaptic clefts of peripheral nerve endings and is used to treat the Lambert-Eaton myasthenic syndrome. Amifampridine is associated with a low rate of transient serum enzyme elevations during therapy but has not been linked with instances of clinically apparent acute liver injury. ... in EUR : FIRDAPSE® is a medicine that contains the active substance amifampridine. It is available as tablets (10 mg). Firdapse is used to treat the symptoms of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a disease in which patients have muscle weakness because of a failure of the nerves to transmit electrical impulses to the muscles. Because the number of patients with LEMS is low, the disease is considered ‘rare’, and Firdapse was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 18 December 2002. The medicine can only be obtained with a prescription. https://www.ema.europa.eu/en/medicines/human/EPAR/firdapse in USA : FIRDAPSE® is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. in USA : RUZURGI is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age. |
Lien associé : | full text available on National Library of Medicine |
Pubmed / DOI : | Pubmed : 31643190 |
Date mise à jour : | 10/10/2022 |
N° Profil MNM : | 2019102 |
En ligne : | http://www.ncbi.nlm.nih.gov/pubmed/31643190 |